Guillaume Lhermie

Dr. Guillaume Lhermie


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2017 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
GLGuillaume Lhermie
Guillaume Lhermie
YGYrjö T. Gröhn
Yrjö T. Gröhn
DRDidier Raboisson
Didier Raboisson
The growing concern regarding emergence of bacteria resistant to antimicrobials and their potential for transmission to humans via animal production has led various authorities worldwide to implement measures to decrease antimicrobial use in livestock production. These measures are influenced by those implemented in human medicine, and emphasize the importance of antimicrobial stewardship, surveillance, infection prevention and control and research. In food producing animals, unlike human medicine, antimicrobials are used to control diseases which cause economic losses. This major difference may explain the failure of the public policies implemented to control antimicrobial usage. Here we first review the specific factors influencing antimicrobial use across the farm animal sector and highlighting the farmers’ decision-making process of antimicrobial use. We then discuss the efficiency of existing regulations implemented by policy makers, and assess the need for alternative strategies, such as substitution between antimicrobials and other measures for infectious disease control. We also discuss the interests of regulating antimicrobial prices. Finally, we emphasize the value of optimizing antimicrobial regimens, and developing veterinary precision medicine to achieve clinical efficacy in animals while limiting negative impacts on public health. The fight against antimicrobial resistance requires both a reduction and an optimization of antimicrobial consumption. The set of actions currently implemented by policy makers does not adequately address the economic interests of farmers’ use of antimicrobials.

13 November 2018 in Nature Sustainability
Verified
Journal Article
Closed access
PDF file
LPLiving With Resistance Project
Living With Resistance Project
PJPeter Søgaard Jørgensen
Peter Søgaard Jørgensen
AAAthena Aktipis
Athena Aktipis
ZBZachary Brown
Zachary Brown
YCYves Carrière
Yves Carrière
SCScott P. Carroll
Scott P. Carroll

18 February 2020 in Preventive Veterinary Medicine
Verified
Journal Article
Closed access
CCCasey L. Cazer
Casey L. Cazer
EEErin R.B. Eldermire
Erin R.B. Eldermire
GLGuillaume Lhermie
Guillaume Lhermie
SMSarah A. Murray
Sarah A. Murray
HSHarvey Morgan Scott
Harvey Morgan Scott
YGYrjö T. Gröhn
Yrjö T. Gröhn

2 April 2020 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
GLGuillaume Lhermie
Guillaume Lhermie
RRRoberto Marcello La Ragione
Roberto Marcello La Ragione
JWJ Scott Weese
J Scott Weese
JOJohn Elmerdahl Olsen
John Elmerdahl Olsen
JCJens Peter Peter Christensen
Jens Peter Peter Christensen
LGLuca Guardabassi
Luca Guardabassi
Background: Among the measures taken to preserve the clinical efficacy of highest priority critically important antimicrobials (HP-CIAs), the WHO has recommended avoiding their use in food-producing animals. Little is known regarding the indications for which different antimicrobial classes are used in animals, even in countries where data on antimicrobial use are available. Objectives: To outline, in a narrative review, the diseases for which HP-CIAs are used in veterinary medicine, highlighting incongruences with international guidelines and disease conditions where effective alternatives to HP-CIAs are missing. Methods: Scientific literature, national reports and expert opinion were used to describe the indications for the use of HP-CIAs in the main food-producing (pigs, cattle and poultry) and companion (horses, dogs and cats) animal species. Results: The most common indications for use of HP-CIAs are enteric and respiratory infections in pigs, cattle and poultry, urogenital infections in dogs and cats and respiratory infections in horses. In some instances, no valid and convenient alternatives to colistin and macrolides are available against certain porcine enteric and bovine respiratory pathogens. Effective, legal and convenient alternatives to HP-CIAs are also lacking for managing common infections in cats, for which oral administration is difficult, Rhodococcus equi infections in horses, some enteric and respiratory infections in poultry and MDR infections in all companion animal species. Conclusions: Future research and stewardship programmes should focus on the disease conditions identified by this review to reduce the use of HP-CIAs in the veterinary sector.

28 February 2020 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
SRSarah N. Robbins
Sarah N. Robbins
RGRobert Goggs
Robert Goggs
GLGuillaume Lhermie
Guillaume Lhermie
DLDenise F. Lalonde-Paul
Denise F. Lalonde-Paul
JMJulie Menard
Julie Menard
Background: Antimicrobial use contributes to emergence of antimicrobial resistance. It was hypothesized that antimicrobial prescribing behavior varies between the emergency (ER) and critical care (CC) services in a veterinary teaching hospital. This study aimed to: (i) describe antimicrobial prescribing patterns in the ER and CC services; (ii) assess adherence to stewardship principles; (iii) evaluate the prevalence of multidrug resistant (MDR) bacterial isolates. Methods: Institution electronic medical records were queried for all antimicrobial prescriptions from the ER and CC services between 1/1/2017 and 12/31/2017. Prescriptions were manually reviewed, and the following data recorded: drug, dosage, duration, diagnosis, outcome, hospitalization duration, culture submission, and susceptibility results. Results: There were 5,091 ER visits, of which 3,125 were not transferred to another service. Of these emergency visits, 516 (16.5%) resulted in 613 antimicrobial drug prescriptions. The most commonly prescribed drugs for the ER were amoxicillin/clavulanate (n = 243, 39.6%), metronidazole (n = 146, 23.8%), and ampicillin/sulbactam (n = 55, 9.0%). The most common reasons for antimicrobial prescriptions were skin disease (n = 227, 37.0%), gastrointestinal disease (n = 173, 28.2%), and respiratory disease (n = 50, 8.2%). For ER patients 18 cultures were submitted, equivalent to a 3.5% submission rate. The CC service managed 311 case visits for 822 patient days. Of these, 133 case visits (42.7%) resulted in 340 prescriptions. The most commonly prescribed drugs for the CC service were ampicillin/sulbactam (n = 103, 30.3%), enrofloxacin (n = 75, 22.1%), and metronidazole (n = 59, 17.4%). The most common reasons for antimicrobial prescriptions were gastrointestinal disease (n = 106, 31.2%), respiratory disease (n = 71, 20.9%), and sepsis (n = 61, 17.9%). On the CC service, 46 patients had ≥1 culture submitted, equivalent to a 34.6% submission rate. Of patients prescribed antimicrobials, 13/38 (34%) with urinary tract disease, 2/28 (7%) with pneumonia, 1/11 (9%) with canine infectious respiratory disease complex and 2/8 (25%) with feline upper respiratory infection were compliant with published guidelines. Conclusions: Antimicrobial prescription was common in both ER and CC services and followed similar patterns. Adherence to published guidelines for urinary and respiratory infections was poor.

16 June 2020 in Frontiers in Public Health
Verified
Journal Article
Open access
DRDidier Raboisson
Didier Raboisson
GLGuillaume Lhermie
Guillaume Lhermie
COVID-19 (Corona virus disease 2019) lockdown lifting requires at short and medium terms a holistic and evidence-based approach of health population management, based on combining risk factors and bio-economic outcomes including actors’ behaviors. This dynamic and global approach of health control is necessary to deal with the new paradigm of living with an infectious disease disrupting our individual freedom and behaviors. The challenge for policymakers consists of defining a lockdown lift method and follow-up (middle term rules) that best meets resumption of economic activity, societal well-being and containment of the outbreak. There is no simple and ready-to-use way for this since it means considering several competing objectives at the same time and continuously adapting the strategy and rules, ideally at local scale. We propose a framework to create a precision evidence-based health policy that simultaneously considers public health, economic and societal dimensions while accounting for constraints and uncertainty. It is based on four following principles: integrating multiple and heterogeneous information, accepting to navigate with uncertainty, adjusting the strategy dynamically with feedback mechanisms, and managing clusters through a multi-scalar conception. The evidence-based policy intervention for COVID-19 obtained includes scientific background via epidemiologic modelling and bioeconomic modelling. A set of quantitative and qualitative indicators are used as feedback to precisely monitor the societal-economic-epidemiological dynamics, allowing tightening or loosening measures before the epidemic damage may (re-)occur. This altogether allows an evidence-based policy that steers the strategy with precision and avoid any political shock.